The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Abstract
Phencyclidine (PCP), a dissociative anesthetic and widely abused psychotomimetic drug, and MK-801, a potent PCP receptor ligand, have neuroprotective properties stemming from their ability to antagonize the excitotoxic actions of endogenous excitatory amino acids such as glutamate and aspartate. There is growing interest in the potential application of these compounds in the treatment of neurological disorders. However, there is an apparent neurotoxic effect of PCP and related agents (MK-801, tiletamine, and ketamine), which has heretofore been overlooked: these drugs induce acute pathomorphological changes in specific populations of brain neurons when administered subcutaneously to adult rats in relatively low doses. These findings raise new questions regarding the safety of these agents in the clinical management of neurodegenerative diseases and reinforce concerns about the potential risks associated with illicit use of PCP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benveniste, H., Drejer, J., Schousboe, A., & Diemer, N. H. (1984) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1984.tb05396.x · Cited by 2,859
The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
Wong, E. H., Kemp, J. A., Priestley, T., Knight, A. R., Woodruff, G. N., & Iversen, L. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.7104 · Cited by 1,819
Gill, R., Foster, A., & Woodruff, G. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-10-03343.1987 · Cited by 640
Quantitative Cytoarchitectural Studies of the Cerebral Cortex of Schizophrenics
Benes, F. M. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800010033004 · Cited by 502
Non-competitive antagonists of excitatory amino acid receptors
Kemp, J. A., Foster, A. C., & Wong, E. H. F. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90176-7 · Cited by 498
Excitatory amino acid transmission: Neurology and neurobiology, volume 24
Hicks, T. P., Lodge, D., McClennan, H., Hardy, J. A., & Cowburn, R. F. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80857-8 · Cited by 432
GLUTAMATE-INDUCED NEURONAL NECROSIS IN THE INFANT MOUSE HYPOTHALAMUS: An Electron Microscopic Study
OLNEY, J. W. (1971) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-197101000-00008 · Cited by 415
Self-citationSpecific [3H]phencyclidine binding in rat central nervous system.
Zukin, S. R., & Zukin, R. S. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.10.5372 · Cited by 380
Systemic Cholinergic Agents Induce Seizures and Brain Damage in Lithium-Treated Rats
Honchar, M. P., Olney, J. W., & Sherman, W. R. (1983) · Science · doi:10.1126/science.6301005 · Cited by 366
Self-citationInteraction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes.
Vincent, J. P., Kartalovski, B., Geneste, P., Kamenka, J. M., & Lazdunski, M. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4678 · Cited by 263
Cited by
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Self-citationJentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Excitotoxicity and stroke: Identifying novel targets for neuroprotection
Lai, T. W., Zhang, S., & Wang, Y. T. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.006 · Cited by 1,106
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Self-citationSchmued, L. C., Albertson, C., & Slikker, W. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01387-x · Cited by 994
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
NMDA Antagonist Neurotoxicity: Mechanism and Prevention
Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991) · Science · doi:10.1126/science.1835799 · Cited by 841
Self-citationWhite Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction
Davis, K. L., Stewart, D. G., Friedman, J. I., Buchsbaum, M., Harvey, P. D., Hof, P. R., Buxbaum, J., & Haroutunian, V. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.443 · Cited by 793
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
Malhotra, M. D. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 680
Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin
Jevtović-Todorović, V., Todorovć, S. M., Mennerick, S., Powell, S., Dikranian, K., Benshoff, N., Zorumski, C. F., & Olney, J. W. (1998) · Nature Medicine · doi:10.1038/nm0498-460 · Cited by 676
Self-citationCerebral hypoxia: some new approaches and unanswered questions
Choi, D. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-08-02493.1990 · Cited by 671
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
Chen, H., Pellegrini, J., Aggarwal, S., Lei, S., Warach, S., Jensen, F., & Lipton, S. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 629
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604
Ketamine: Teaching an Old Drug New Tricks
Kohrs, R., & Durieux, M. E. (1998) · Anesthesia & Analgesia · doi:10.1097/00000539-199811000-00039 · Cited by 604
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
The dysconnection hypothesis (2016)
Friston, K., Brown, H. R., Siemerkus, J., & Stephan, K. E. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.07.014 · Cited by 561
Steele, R. J., & Morris, R. G. M. (1999) · Hippocampus · doi:10.1002/(sici)1098-1063(1999)9:2<118::aid-hipo4>3.0.co;2-8 · Cited by 561
Carpenter, W. T., & Buchanan, R. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403103301006 · Cited by 510
Excitotoxicity and the NMDA receptor -- still lethal after eight years
Rothman, S. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93869-y · Cited by 508
Clinical Experience With Excitatory Amino Acid Antagonist Drugs
Muir, K. W., & Lees, K. R. (1995) · Stroke · doi:10.1161/01.str.26.3.503 · Cited by 502
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Loddick, S. A., & Rothwell, N. J. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00017 · Cited by 463
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 436
Dal Canto, M. C., & Gurney, M. E. (1995) · Brain Research · doi:10.1016/0006-8993(95)00063-v · Cited by 435
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
Glutamate: its role in learning, memory, and the aging brain
McEntee, W. J., & Crook, T. H. (1993) · Psychopharmacology · doi:10.1007/bf02253527 · Cited by 403
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.805 · Cited by 392
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Glutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK?
Knapska, E., & Kaczmarek, L. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.007 · Cited by 370
Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites
Moroni, F. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00196-x · Cited by 346
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia
Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G., & Grecksch, G. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00080-0 · Cited by 339
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 336
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
Spatial learning without NMDA receptor-dependent long-term potentiation
Saucier, D., & Cain, D. P. (1995) · Nature · doi:10.1038/378186a0 · Cited by 317
MATTSON, M. P., & SCHEFF, S. W. (1994) · Journal of Neurotrauma · doi:10.1089/neu.1994.11.3 · Cited by 309
PCP: from pharmacology to modelling schizophrenia
Morris, B. J., Cochran, S. M., & Pratt, J. A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.008 · Cited by 308
Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers
Adler, C., Goldberg, T., Malhotra, A., Pickar, D., & Breier, A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00556-8 · Cited by 304
Ellison, G. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00014-g · Cited by 303
Acute and chronic effects of ketamine upon human memory: a review
Morgan, C. J. A., & Curran, H. V. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0572-3 · Cited by 302
Drug‐induced Apoptotic Neurodegeneration in the Developing Brain
Olney, J. W., Wozniak, D. F., Jevtovic‐Todorovic, V., Farber, N. B., Bittigau, P., & Ikonomidou, C. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00467.x · Cited by 298
Self-citationGroup I metabotropic glutamate receptors: implications for brain diseases
Bordi, F., & Ugolini, A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00095-1 · Cited by 295
Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia
Kehrer, C. (2008) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.006.2008 · Cited by 287
Konradi, C., Leveque, J.-C., & Hyman, S. E. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-13-04231.1996 · Cited by 283
Deep posteromedial cortical rhythm in dissociation
Vesuna, S., Kauvar, I. V., Richman, E., Gore, F., Oskotsky, T., Sava-Segal, C., Luo, L., Malenka, R. C., Henderson, J. M., Nuyujukian, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2731-9 · Cited by 281
Prolonged seizures and cellular injury: Understanding the connection
Fujikawa, D. G. (2005) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2005.08.003 · Cited by 273
Morris, G. F., Bullock, R., Marshall, S. B., Marmarou, A., Maas, A., _, _., & Marshall, L. F. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.91.5.0737 · Cited by 273
Correll, G. E., Maleki, J., Gracely, E. J., Muir, J. J., & Harbut, R. E. (2004) · Pain Medicine · doi:10.1111/j.1526-4637.2004.04043.x · Cited by 271
Mouri, A., Noda, Y., Enomoto, T., & Nabeshima, T. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.019 · Cited by 266
Ketamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254
Klockgether, T., Turski, L., Honoré, T., Zhang, Z., Gash, D. M., Kurlan, R., & Greenamyre, J. T. (1991) · Annals of Neurology · doi:10.1002/ana.410300513 · Cited by 258
Lipton, S. A. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90198-u · Cited by 256
Fluoro-Jade: Novel Fluorochromes for Detecting Toxicant-Induced Neuronal Degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Toxicologic Pathology · doi:10.1177/019262330002800111 · Cited by 254
Glutamatergic model psychoses: prediction error, learning, and inference
Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.163 · Cited by 229
Millière, R. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00245 · Cited by 206
Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment
Marquard, J., Otter, S., Welters, A., Stirban, A., Fischer, A., Eglinger, J., Herebian, D., Kletke, O., Klemen, M. S., Stožer, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3822 · Cited by 161
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Camacho, A., & Massieu, L. (2006) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.05.014 · Cited by 150
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
Gomes, F. V., Llorente, R., Del Bel, E. A., Viveros, M.-P., López-Gallardo, M., & Guimarães, F. S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.015 · Cited by 147
Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia†
Greene, R. (2001) · Hippocampus · doi:10.1002/hipo.1072 · Cited by 140
Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113
Lewén, A., Li, G. L., Olsson, Y., & Hillered, L. (1996) · Brain Research · doi:10.1016/0006-8993(96)00081-9 · Cited by 90
Do hallucinogens cause residual neuropsychological toxicity?
Halpern, J. H., & Pope, H. G. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00129-x · Cited by 82
Picard, N., Takesian, A. E., Fagiolini, M., & Hensch, T. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0341-9 · Cited by 71
Onwordi, E. C., Whitehurst, T., Mansur, A., Statton, B., Berry, A., Quinlan, M., O’Regan, D. P., Rogdaki, M., Marques, T. R., Rabiner, E. A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01515-3 · Cited by 55
Okamoto, M., Mori, S., & Endo, H. (1994) · Brain Research · doi:10.1016/0006-8993(94)91217-3 · Cited by 59
Zapata, A., Capdevila, J. L., Tarrason, G., Adan, J., Martı́nez, J. M., Piulats, J., & Trullas, R. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01134-1 · Cited by 34
Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Rasmussen, K. G. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.002 · Cited by 32
Bettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15080997 · Cited by 31
BW1003C87 and NBQX but not CGS19755 reduce glutamate release and cerebral ischemic necrosis
Gaspary, H. L., Simon, R. P., & Graham, S. H. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90733-1 · Cited by 28
Positive association of Phencyclidine‐responsive genes, PDE4A and PLAT, with schizophrenia
Deng, X., Takaki, H., Wang, L., Kuroki, T., Nakahara, T., Hashimoto, K., Ninomiya, H., Arinami, T., Inada, T., Ujike, H., et al. (2011) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31233 · Cited by 21
Astrocytic Edema in CNS Trauma
Kimelberg, H. K. (1992) · Journal of Neurotrauma · doi:10.1177/089771519200901s06 · Cited by 11
A ketamine-induced rat model of tardive dyskinesia
Marco, L. A., & Joshi, R. S. (1992) · Progress in Neurobiology · doi:10.1016/0301-0082(92)90042-d · Cited by 10
Sedation in the emergency department: A complex and multifactorial challenge
Kennedy, R. M. (2015) · Pediatric Sedation Outside of the Operating Room · doi:10.1007/978-1-4939-1390-9_19 · Cited by 4
Sedation in the Emergency Department: A Complex and Multifactorial Challenge
Kennedy, R. M. (2021) · Pediatric Sedation Outside of the Operating Room · doi:10.1007/978-3-030-58406-1_22 · Cited by 1
Metadata
- Authors
- Olney, J. W., Labruyere, J., & Price, M. T.
- Venue
- Science
- Published
- 1989-06-16
- Volume
- 244
- Issue
- 4910
- Pages
- 1360-1362
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1981234599
- Cited by
- 1,237
- References
- 21
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.